Last updated on August 2018

Study Evaluating the Safety Tolerability PK and Activity of Topical ATx201 Gel in Outpatients With Impetigo

Brief description of study

This is a Phase 2 study evaluating the safety, tolerability, systemic exposure, and activity of topical ATx201 GEL (2% and 4%) treatment for 1, 2, or 5 days in outpatients with primary nonbullous or bullous impetigo.

Clinical Study Identifier: NCT03429595

Contact Investigators or Research Sites near you

Start Over

Site 003

AntibioTx Investigative Site
Pretoria, South Africa